Neurochemical underpinnings in bipolar disorder and epilepsy

Epilepsia

Volumn 46, Issue SUPPL. 4, 2005, Pages 26-30

  Amann, Benedikt ^a,b   Grunze, Heinz ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bipolar disorder; Early genes; Epilepsy; Ion channels; Neurotransmitter

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CALCIUM ANTAGONIST; CARBAMAZEPINE; DOPAMINE; EXCITATORY AMINO ACID; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; PHENYTOIN; POTASSIUM; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ION CHANNEL; NEUROPROTECTIVE AGENT;

BIPOLAR DISORDER; CONTROLLED STUDY; DISEASE COURSE; EPILEPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR TRANSPORT; ION TRANSPORT; KINDLING; MEMBRANE CURRENT; NEUROCHEMISTRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ARTICLE; GENETIC TRANSCRIPTION; METABOLISM; PHYSIOLOGY; SECOND MESSENGER;

ANTICONVULSANTS; BIPOLAR DISORDER; EPILEPSY; HUMANS; ION CHANNELS; KINDLING, NEUROLOGIC; LITHIUM; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; SECOND MESSENGER SYSTEMS; TRANSCRIPTION, GENETIC;

EID: 20544478555     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.463006.x     Document Type: Review

References (68)

1. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-54.
2. Fasmer OB. The prevalence of migraine in patients with bipolar and unipolar affective disorders. Cephalgia 2001;21:894-9.
3. Robertson MM. Mood disorder in epilepsy. In: McConnell H, Snyder PJ, eds. Psychiatric comorbidity in epilepsy. Washington, DC: American Psychiatric Press, 1998:133-67.
4. Hantouche EG, Akiskal HS, Lancrenon S, et al. Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord 1998;50:163-73.
5. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999;34:109-22.
6. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-5.
7. Kraepelin E. Psychiatrie. Munchen: 8e Auflage, H. Band. 1321-6.
8. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 2000;48:445-57.
9. Post RM, Uhde TW, Putnam FW, et al. Kindling and carbamazepine in affective illness. J Nerv Ment Disord 1982;170:717-31.
10. Amann B, Grunze H. The evolution of antiepileptic drugs for mood disorder and their main mechanism of action. Expert Rev Neurotherapeutics 2003;3:107-17.
11. Stoll AL, Banov M, Kolbrener M, et al. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994;14:311-3.
12. Levy AB, Drake ME, Shy KE. EEG evidence of epileptiform paroxysms in rapid cycling bipolar patients. J Clin Psychiatry 1988;49:232-4.
13. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001;2:28-36.
14. Loscher W, Fischer JE, Nau H, et al. Valproic acid in amygdalakindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment. J Pharmacol Exp Ther 1989;250:1067-78.
15. O'Donnell RA, Miller AA. The effect of lamotrigine upon development of cortical kindled seizures in the rat. Neuropharmacology 1991;30:253-8.
16. Morimoto K, Sato H, Yamamoto Y, et al. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 1997;38:966-74.
17. Petty F. Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? Clin Chem 1994;40:296-302.
18. Granger P, Biton B, Faure C, et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol 1995;47:1189-96.
19. Emrich HM, von Zerssen D, Kissling W, et al. On a possible role of GABA in mania: therapeutic efficacy of sodium valproate. Adv Biochem Psychopharmacol 1981;26:287-96.
20. Mishory A, Yaroslavsky Y, Bersudsky Y, et al. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000;157:463-5.
21. Cunningham MO, Dhillon A, Wood SJ, et al. Reciprocal modulation of glutamate and GABA release may underlie the anticonvulsant effect of phenytoin. Neuroscience 2000;95:343-51.
22. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the pre-clinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41:33-9.
23. Lampe H, Bigalke H. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1990;1:26-8.
24. Loscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 1993;18:485-502.
25. Teoh H, Fowler LJ, Bowery NG. Effect of lamotrigine on the electrically evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. Neuropharmacology 1995;34:1273-8.
26. Waldmeier PC, Baumann PA, Wicki P, et al. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995;45:1907-13.
27. 14C]guanidinium ion flux through GluR6 channels in transtected BHK cells using Cytostar-T scintillating microplates. Epilepsia 2000;41:848-51.
28. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997;17:185-9.
29. Lyseng-Williamson KA, Perry CM. Aripiprazole in acute mania associated with bipolar I disorder. CNS Drugs. 2004;18:367-76.
30. Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry 1992;33:115-20.
31. Loscher W, Honack D. Valproate and its major metabolite E-2-envalproate induce different effects on behaviour and brain monoamine metabolism in rats. Eur J Pharmacol 1996;28299:61-7.
32. 18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry 2002;159:768-74.
33. Clinckers R, Smolders I, Meurs A, et al. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J Neurochem 2004;89:834-43.
34. van Praag HM, de Haan S. Central serotonin metabolism and frequency of depression. Psychiatry Res 1979;1:219-24.
35. Maes M, Calabrese J, Jayathilake K, et al. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res 1997;71:67-76.
36. Hegerl U, Wulff H, Muller-Oerlinghausen B. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: a replication study. Psychiatry Res 1992;44:181-90.
37. Whitton PS, Oreskovic D, Jernej B, et al. Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain. J Pharm Pharmacol 1985;37:199-200.
38. 2+. Eur J Pharmacol 1997;328:153-62.
39. Southam E, Kirkby D, Higgins GA, et al. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol 1998;358:19-24.
40. Jobe PC. Affective disorder and epilepsy comorbidity: implications for development of treatments, preventions and diagnostic approaches. Clin EEG Neurosci 2004;35:53-68.
41. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36:S2-12.
42. Mishory A, Yaroslavsky Y, Bersudsky Y, et al. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000;157:463-5.
43. Applebaum J, Levine J, Belmaker RH. Intravenous fosphenytoin in acute mania. J Clin Psychiatry 2003;64:408-9.
44. Mishory A, Winokur M, Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord 2003;5:464-7.
45. Speckmann EJ, Straub H, Kohling R. Contribution of calcium ions to the generation of epileptic activity and antiepileptic calcium antagonism. Neuropsychobiology 1993;27:122-6.
46. Dubovsky SL, Thomas M, Hijazi A, et al. Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 1994;243:229-34.
47. van Calker D, Forstner U, Bohus M, et al. Increased sensitivity to agonist stimulation of the Ca2+ response in neutrophils of manic-depressive patients: effect of lithium therapy. Neuropsychobiology 1993;27:180-3.
48. Walden J, Grunze H, Bingmann D, et al. Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies. Eur Neuropsychopharmacol 1992;2:455-62.
49. Altrup U, Gerlach G, Reith H, et al. Effects of valproate in a model nervous system (buccal ganglia of Helix pomatia), I: antiepileptic actions. Epilepsia 1992;33:743-52.
50. Grunze H, Amann B, Walden J. How might antoconvulsant drugs work. In: Trimble M, Schmitz B, eds. Bipolar disorder in seizures: affective disorders and anticonvulsants drugs. Guildford, UK: Clarius Press, 2002:117-30.
51. Wood AJ, Elphick M, Aronson JK, et al. The effect of lithium on cation transport measured in vivo in patients suffering from bipolar affective illness. Br J Psychiatry 1989;155:504-10.
52. Olpe H, Kolb CN, Hausdorf A, et al. 4-Aminopyridine and barium chloride attenuate the anti-epileptic effect of carbamazepine in hippocampal slices. Experientia 1991;47:254-7.
53. Walden J, Altrup U, Reith H, et al. Effects of valproate on early and late potassium currents of single neurons. Eur Neuropsychopharmacol 1993;3:137-41.
54. Grunze H, von Wegerer J, Greene RW, et al. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 1998;38:131-8.
55. Jensen JB, Mork A. Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. Eur Neuropsychopharmacol 1997;7:173-9.
56. Bebchuk JM, Arfken CL, Dolan-Manji S, et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000;57:95-7.
57. Yuan PX, Huang LD, Jiang YM, et al. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001;276:31674-83.
58. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression: a prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999;274:6039-42.
59. Chen G, Zeug WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999;72:879-82.
60. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998;3:2642-7.
61. Mark RJ, Ashford JW, Goodman Y, et al. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995;16:187-98.
62. Siesinger PA, Singer HS. Effects of anticonvulsants on cell growth and enzymatic and receptor binding activity in a neuroblastoma × glioma hybrid cell culture. Epilepsia 1987;28:214-21.
63. Rataud J, Debarnot F, Mary V, et al. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett 1994;172:19-23.
64. Yang Y, Shuaib A, Li Q, et al. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998;804:169-76.
65. Kosel M, Schlaepfer TE. Beyond the treatment of epilepsy: new applications of vagus nerve stimulation in psychiatry. CNS Spectr 2003;8:515-21.
66. Elger CE, Hoppe C. Vagus nerve stimulation and mood. In: Trimble M, Schmitz B, eds. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press, 2002:283-98.
67. Nagai Y, Goldstein LH, Fenwick PB, et al. Clinical efficacy of galvanic skin response biofeedback training in reducing seizures in adult epilepsy: a preliminary randomized controlled study. Epilepsy Behav 2004;5:216-23.
68. Jones S. Psychotherapy of bipolar disorder: a review. J Affect Disord 2004;80:101-14.